Lexeo Therapeutics (LXEO) Income from Non-Controlling Interests (2023)
Lexeo Therapeutics (LXEO) reported Income from Non-Controlling Interests of -$258000.0 for Q4 2023, up 5.15% sequentially from -$272000.0 in Q3 2023.
Lexeo Therapeutics (LXEO) Income from Non-Controlling Interests (2023) Analysis & Trends
Lexeo Therapeutics (LXEO) has 1 years of Income from Non-Controlling Interests data on file, last reported at -$258000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - | - |
| 2 | Nanobiotix | 1,947.22 Bn | 1,947.15 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.21 Bn | 468.42 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 123.29 Bn | 116.04 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.63 Bn | 51.45 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.79 Bn | 37.79 Bn | - | - |
| 10 | Lexeo Therapeutics | 385.62 Mn | 385.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -258,000.00 |
| Sep 30, 2023 | -272,000.00 |